Physician profile
Peter Zullo
NPI 1043393580
$2,688.01
in general payments reported to CMS, 2019-2025
25 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $345 · 2021: $450 · 2022: $19.53 · 2023: $426 · 2024: $692 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.98 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $275.50 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $230.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $223.75 | 2019-2025 | |
| Abbvie INC. | $214.50 | 2023-2025 | Vraylar, Ubrelvy |
| Abbott Laboratories | $177.04 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $164.87 | 2020-2024 | Lexiscan, Veozah |
| E.R. Squibb & Sons, L.L.C. | $153.64 | 2019-2023 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $117.17 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Shield Therapeutics INC | $107.27 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $92.61 | 2020-2021 | |
| Amarin Pharma, INC. | $82.15 | 2019-2021 | |
| Amgen INC. | $79.95 | 2019-2024 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $70.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.68 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.09 | 2019-2025 | Jardiance, Tradjenta |
| Mylan Specialty L.P. | $34.55 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $34.29 | 2019 | |
| Dexcom, INC. | $33.43 | 2023-2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $28.30 | 2019-2020 | |
| Exact Sciences Corporation | $24.39 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $23.87 | 2024 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $21.23 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.15 | 2021 | |
| Allergan, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Zullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.